Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6166MR)

This product GTTS-WQ6166MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6166MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14098MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ10863MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ12569MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ9223MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ15041MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ7409MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ228MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ4768MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BR3-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW